

Roopen Arya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/301702/publications.pdf>

Version: 2024-02-01

139
papers

3,646
citations

168829

31
h-index

169272

56
g-index

145
all docs

145
docs citations

145
times ranked

4862
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital. British Journal of Haematology, 2022, 196, .	1.2	3
2	The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause. Menopause, 2022, Publish Ahead of Print, 580-589.	0.8	1
3	Venous thromboembolism in patients hospitalised with COVID-19 in England. Thrombosis Research, 2022, 213, 138-144.	0.8	9
4	Preventing VTE following total hip and knee arthroplasty: Is prediction the future?. Journal of Thrombosis and Haemostasis, 2021, 19, 41-45.	1.9	18
5	Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic. Thrombosis Research, 2021, 197, 192-194.	0.8	11
6	More on enoxaparin thromboprophylaxis in pregnancy: A review of 10 years' experience from King's College Hospital. Journal of Thrombosis and Haemostasis, 2021, 19, 304-308.	1.9	3
7	Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis â€• Reply to Jacobs & Ryan comment. Journal of Thrombosis and Haemostasis, 2021, 19, 872-873.	1.9	0
8	An international survey of low molecular weight heparin prescribing in the context of antenatal venous thromboembolism. Thrombosis Research, 2021, 200, 99-101.	0.8	2
9	Comparison of rotational thromboelastometry parameters with 20-minute whole blood clotting test as a predictor of envenoming in Russell's viper bite patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 561-565.	0.7	2
10	Three-month follow-up of pulmonary embolism in patients with COVID-19. Thrombosis Research, 2021, 201, 113-115.	0.8	18
11	Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination â€• A report of two UK cases. Brain, Behavior, and Immunity, 2021, 95, 514-517.	2.0	102
12	Rivaroxaban in acute venous thromboembolism: UK prescribing experience. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12607.	1.0	4
13	Adherence to rivaroxaban for the treatment of venous thromboembolismâ€•Results from the FIRST registry. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12614.	1.0	3
14	Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study. Thrombosis Research, 2021, 208, 162-169.	0.8	5
15	Annotation: travel and thrombosis. British Journal of Haematology, 2020, 188, 838-843.	1.2	4
16	Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry. TH Open, 2020, 04, e1-e11.	0.7	2
17	Pulmonary embolism mortality trends in the European regionâ€•"too good to be true?. Lancet Respiratory Medicine, the, 2020, 8, e2.	5.2	3
18	The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health, 2020, 26, 181-209.	0.3	82

#	ARTICLE	IF	CITATIONS
19	Obesity and venous thromboembolism. , 2020, , 245-253.		1
20	Automated Inferior Vena Cava Filter Retrieval Requests and Hematology Liaison Improves Retrieval and Reduces the Use of Temporary Inferior Vena Cava Filters. TH Open, 2020, 04, e116-e118.	0.7	1
21	Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood, 2020, 136, 1347-1350.	0.6	164
22	Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy. Kidney International Reports, 2020, 5, 1377-1380.	0.4	7
23	Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?. Blood, 2020, 136, 1783-1785.	0.6	7
24	Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2296-2307.	1.9	37
25	Comment on Comparison of three transfusion protocols prior to central venous catheterisation in patients with cirrhosis; a randomised controlled trial. Journal of Thrombosis and Haemostasis, 2020, 18, 753-754.	1.9	1
26	Pulmonary embolism in hospitalised patients with COVID-19. Thrombosis Research, 2020, 195, 95-99.	0.8	75
27	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. Journal of Thrombosis and Haemostasis, 2020, 18, 834-843.	1.9	22
28	A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1144, 122095.	1.2	14
29	Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. Journal of Thrombosis and Haemostasis, 2020, 18, 518-519.	1.9	0
30	Hemostatic derangement in leptospirosis: A prospective cross-sectional study. International Journal of Critical Illness and Injury Science, 2020, 10, 28.	0.2	1
31	Patient experience of pregnancy-related venous thrombosis: A phenomenological study. Thrombosis Research, 2019, 183, 86-90.	0.8	5
32	Pregnancy outcomes in women with mechanical prosthetic heart valves. Thrombosis Research, 2019, 181, S37-S40.	0.8	3
33	Progress in the monitoring of direct oral anticoagulant therapy. British Journal of Haematology, 2019, 184, 912-924.	1.2	33
34	Direct oral anticoagulants for the management of venous thromboembolism in patients with HIV " a single centre experience. British Journal of Haematology, 2019, 186, e148-e151.	1.2	5
35	What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial. Journal of Thrombosis and Thrombolysis. 2019. 48. 315-322.	1.0	8
36	Venous thromboembolism. Clinical Medicine, 2019, 19, 262.1-262.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. <i>Thrombosis Journal</i> , 2019, 17, 6.	0.9	15
38	Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide. <i>Thrombosis Research</i> , 2019, 176, 36-38.	0.8	5
39	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients. <i>Thrombosis Journal</i> , 2019, 17, 24.	0.9	21
40	Women's views, adherence and experience with postnatal thromboprophylaxis. <i>Thrombosis Research</i> , 2019, 173, 85-90.	0.8	12
41	Prothrombin times in the presence of edoxaban <i>in vivo</i> experience from King's College hospital. <i>British Journal of Haematology</i> , 2019, 184, 455-456.	1.2	2
42	The role of preoperative deep vein thrombosis screening in neurooncology. <i>Journal of Neurosurgery</i> , 2018, 130, 38-43.	0.9	9
43	Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study. <i>Thrombosis Research</i> , 2018, 162, 62-68.	0.8	19
44	Single centre experience of the management of superficial vein thrombosis with prophylactic low-molecular-weight heparin. <i>British Journal of Haematology</i> , 2018, 181, 682-684.	1.2	3
45	Re: Pregnancy outcomes in women with mechanical prosthetic heart valves – a prospective descriptive population-based study using the United Kingdom Obstetric Surveillance System (<scp>UKOSS</scp>) data collection system. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 96-96.	1.1	4
46	Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1511-1518.	1.0	9
47	Venous thromboembolism and women's health. <i>British Journal of Haematology</i> , 2018, 183, 346-363.	1.2	24
48	Sub therapeutic rivaroxaban plasma concentrations following administration via Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – A note of caution. <i>Thrombosis Research</i> , 2018, 168, 102-103.	0.8	3
49	Author's reply re: Postpartum venous thromboembolism prophylaxis: harm versus benefit. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1196-1197.	1.1	3
50	Current challenges and future prospects in oral anticoagulant therapy. <i>British Journal of Haematology</i> , 2017, 178, 838-851.	1.2	30
51	Annotation: Developing a national programme for <scp>VTE</scp> prevention. <i>British Journal of Haematology</i> , 2017, 178, 162-170.	1.2	24
52	Re: A comparison of the recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from the major guidelines. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 831-832.	1.1	6
53	The impact of body weight on rivaroxaban pharmacokinetics. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 180-187.	1.0	44
54	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Thrombin Generation in Acute Ischaemic Stroke. <i>Stroke Research and Treatment</i> , 2016, 2016, 1-9.	0.5	8
56	Sneddon's syndrome: it is all in the ectoderm. <i>Practical Neurology</i> , 2016, 16, 300-303.	0.5	7
57	Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature. <i>Drugs - Real World Outcomes</i> , 2016, 3, 1-6.	0.7	34
58	Clinical and laboratory predictors of deep vein thrombosis after acute stroke. <i>Thrombosis Research</i> , 2016, 142, 33-39.	0.8	30
59	Heavy menstrual bleeding on rivaroxaban. <i>British Journal of Haematology</i> , 2016, 173, 314-315.	1.2	53
60	Clinical and laboratory predictors of deep vein thrombosis after acute stroke: Does D-dimer really improve predictive power?. <i>Thrombosis Research</i> , 2016, 146, 133-134.	0.8	1
61	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016, 116, 651-658.	1.8	79
62	Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy "study protocol for The Switching Study: a prospective cohort study. <i>BMC Hematology</i> , 2016, 16, 22.	2.6	5
63	Adherence to long-term anticoagulation treatment, what is known and what the future might hold. <i>British Journal of Haematology</i> , 2016, 174, 30-42.	1.2	55
64	Maternal and pregnancy characteristics affect plasma fibrin monomer complexes and D-dimer reference ranges for venous thromboembolism in pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 466.e1-466.e8.	0.7	17
65	Relationship between development of post-thrombotic syndrome and serial ultrasound, D-dimer, and factor VIII activity after a first deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2016, 4, 28-35.	0.9	13
66	Changing paradigms in the management of deep vein thrombosis. <i>British Journal of Haematology</i> , 2015, 170, 162-174.	1.2	6
67	The prevention of pregnancy-related venous thromboembolism. <i>British Journal of Haematology</i> , 2015, 168, 163-174.	1.2	44
68	New oral anticoagulants: dosing and monitoring. <i>BMJ</i> , The, 2015, 350, h2655-h2655.	3.0	6
69	Normal prothrombin times in the presence of therapeutic levels of apixaban "in vivo" experience from King's College Hospital. <i>British Journal of Haematology</i> , 2015, 169, 152-153.	1.2	12
70	The First Registry: Follow-up in Rivaroxaban Patients in the Setting of Venous Thromboembolism. <i>Blood</i> , 2015, 126, 4737-4737.	0.6	1
71	Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium. <i>BMC Pregnancy and Childbirth</i> , 2014, 14, 384.	0.9	16
72	Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 597-605.	1.0	85

#	ARTICLE	IF	CITATIONS
73	Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. <i>Liver International</i> , 2014, 34, 672-678.	1.9	77
74	The current status of bridging anticoagulation. <i>British Journal of Haematology</i> , 2014, 164, 619-629.	1.2	18
75	Women with unexplained recurrent pregnancy loss do not have evidence of an underlying prothrombotic state: Experience with calibrated automated thrombography and rotational thromboelastometry. <i>Thrombosis Research</i> , 2014, 133, 892-899.	0.8	11
76	Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. <i>Haematologica</i> , 2014, 99, e41-e43.	1.7	33
77	More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban – early experience from King's College Hospital. <i>British Journal of Haematology</i> , 2013, 162, 717-718.	1.2	12
78	Presenting D-dimer and early symptom severity are independent predictors for post-thrombotic syndrome following a first deep vein thrombosis. <i>British Journal of Haematology</i> , 2013, 160, 817-824.	1.2	28
79	Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. <i>British Journal of Haematology</i> , 2013, 161, 764-777.	1.2	23
80	African-Caribbean ethnicity is associated with a hypercoagulable state as measured by thrombin generation. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 40-49.	0.5	31
81	A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: Study protocol and review of the literature. <i>Menopause International</i> , 2013, 19, 127-132.	1.6	12
82	Population Pharmacokinetics of Enoxaparin During the Antenatal Period. <i>Circulation</i> , 2013, 128, 1462-1469.	1.6	48
83	The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. <i>Menopause International</i> , 2013, 19, 59-68.	1.6	117
84	Comprehensive VTE Prevention Program Incorporating Mandatory Risk Assessment Reduces the Incidence of Hospital-Associated Thrombosis. <i>Chest</i> , 2013, 144, 1276-1281.	0.4	47
85	Does IgA antibody against Î22 glycoprotein I increase cardiovascular risk in hemodialysis patients?. <i>Kidney International</i> , 2012, 81, 1164-1166.	2.6	2
86	Women's views on and adherence to low-molecular-weight heparin therapy during pregnancy and the puerperium. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2526-2534.	1.9	28
87	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 500-502.	1.9	3
88	Pregnancy loss and thrombophilia: the elusive link. <i>British Journal of Haematology</i> , 2012, 157, 529-542.	1.2	54
89	Population Pharmacokinetics of Enoxaparin During the Antenatal Period. <i>Blood</i> , 2012, 120, 503-503.	0.6	2
90	How I manage venous thromboembolism in pregnancy. <i>British Journal of Haematology</i> , 2011, 153, 698-708.	1.2	29

#	ARTICLE	IF	CITATIONS
91	Anticoagulating obese patients in the modern era. <i>British Journal of Haematology</i> , 2011, 155, 137-149.	1.2	86
92	Prophylaxis with low-dose low molecular weight heparin during pregnancy and the puerperium: is it effective? A rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1269-1271.	1.9	5
93	Deep vein thrombosis and pulmonary embolism: diagnosis, treatment and prevention. <i>Clinical Medicine</i> , 2011, 11, 465-466.	0.8	5
94	Outcomes From Root Cause Analysis of Hospital-Associated Thrombosis Over Twelve Months: A Single Centre Experience. <i>Blood</i> , 2011, 118, 675-675.	0.6	5
95	Haemostasis and thrombosis in liver disease. <i>British Journal of Haematology</i> , 2010, 148, 507-521.	1.2	85
96	Risk factors for cancer-associated venous thromboembolism in outpatient deep venous thrombosis clinics. <i>British Journal of Haematology</i> , 2010, 150, 640-641.	1.2	1
97	Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. <i>Thrombosis and Haemostasis</i> , 2010, 103, 338-343.	1.8	84
98	New Anticoagulants for Prevention and Treatment of Venous Thromboembolism. <i>Current Vascular Pharmacology</i> , 2010, 8, 373-382.	0.8	2
99	Mean Platelet Volume as a Risk Factor for Deep Vein Thrombosis In An Ethnically Diverse Population. <i>Blood</i> , 2010, 116, 4211-4211.	0.6	0
100	Identifying Patients at High Risk for Deep Vein Thrombosis (DVT) After Acute Stroke Using Clinical and Laboratory Predictors.. <i>Blood</i> , 2010, 116, 3825-3825.	0.6	0
101	More on thromboprophylaxis: Quantifying risk for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 101, 791-794.	1.8	5
102	Impact of venous thromboembolism on survival in patients with malignancy. <i>British Journal of Haematology</i> , 2009, 145, 258-260.	1.2	4
103	Late onset hypogonadism: an alternate cause for night sweats in the haematology clinic. <i>British Journal of Haematology</i> , 2009, 145, 435-437.	1.2	0
104	Is "Virchow's triad" useful? " response to Malone and Agutter. <i>British Journal of Haematology</i> , 2009, 145, 840-841.	1.2	1
105	Venous thromboembolism and ethnicity. <i>British Journal of Haematology</i> , 2009, 146, 369-383.	1.2	78
106	Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation. <i>Journal of Vascular Surgery</i> , 2009, 49, 211-213.	0.6	3
107	Virchow and his triad: a question of attribution. <i>British Journal of Haematology</i> , 2008, 143, 180-190.	1.2	450
108	Venous thromboembolism: racial and ethnic influences. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 169-175.	0.2	5

#	ARTICLE	IF	CITATIONS
109	Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study. <i>Blood</i> , 2008, 112, 3826-3826.	0.6	0
110	Acquired factor V inhibitor after haematopoietic stem cell transplantation. <i>Thrombosis and Haemostasis</i> , 2007, 98, 685-687.	1.8	7
111	Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1141-1142.	1.8	11
112	Derivation and Validation of a Prediction Tool for Venous Thromboembolism: A VERITY Registry Study.. <i>Blood</i> , 2007, 110, 697-697.	0.6	1
113	Haemostasis in Neurosurgery. , 2007, , 91-113.		0
114	Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome. <i>Gastroenterology</i> , 2006, 130, 2031-2038.	0.6	265
115	Extrinsic venous compression: A sufficient explanation for venous thromboembolism due to massive fibroids?. <i>Thrombosis and Haemostasis</i> , 2006, 96, 694-696.	1.8	8
116	Evaluating the Performance of a Previously Reported Risk Score To Predict Venous Thromboembolism: A VERITY Registry Study.. <i>Blood</i> , 2006, 108, 716-716.	0.6	9
117	Low Dose Prothrombin Complex Concentrates Reverse Oral Anticoagulation with Minimal Complications.. <i>Blood</i> , 2006, 108, 891-891.	0.6	1
118	Extrinsic Venous Compression May Not Be a Sufficient Explanation for Venous Thromboembolism Due to Massive Fibroids.. <i>Blood</i> , 2006, 108, 4100-4100.	0.6	0
119	Heparin-induced skin necrosis. <i>British Journal of Haematology</i> , 2005, 129, 712-712.	1.2	8
120	Detection of prothrombin gene polymorphism at position 20209 (PT20209C/T): Pilot study in a black population in the United Kingdom. <i>Thrombosis and Haemostasis</i> , 2005, 93, 179-180.	1.8	19
121	Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.. <i>Blood</i> , 2005, 106, 2588-2588.	0.6	2
122	Coagulation factor levels and venous thrombosis in the black population. <i>Thrombosis and Haemostasis</i> , 2004, 91, 828-830.	1.8	8
123	Venous Thromboembolism in the Black Population. <i>Archives of Internal Medicine</i> , 2004, 164, 1348-9.	4.3	14
124	Reply to Rosendaal et al. <i>British Journal of Haematology</i> , 2003, 120, 368-368.	1.2	0
125	Effects of folic acid supplementation on inflammatory and thrombogenic markers in chronic smokers. A randomised controlled trial. <i>Thrombosis Research</i> , 2003, 110, 13-17.	0.8	41
126	Tests for Hereditary Thrombophilia Are of Limited Value in the Black Population. <i>Stroke</i> , 2003, 34, e236.	1.0	5

#	ARTICLE	IF	CITATIONS
127	Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. <i>Blood</i> , 2003, 101, 101-103.	0.6	78
128	Thrombolysis in pregnancy. <i>Thrombosis and Haemostasis</i> , 2003, 90, 1216-1217.	1.8	38
129	Risk factors for venous thrombosis in the black population. <i>Thrombosis and Haemostasis</i> , 2003, 90, 835-838.	1.8	62
130	Long-haul flights and deep vein thrombosis: a significant risk only when additional factors are also present. <i>British Journal of Haematology</i> , 2002, 116, 653-654.	1.2	81
131	Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. <i>British Journal of Obstetrics and Gynaecology</i> , 2001, 108, 327-329.	0.9	20
132	Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation. <i>Blood</i> , 2001, 97, 2525-2526.	0.6	12
133	Internal jugular vein thrombosis after assisted conception therapy. <i>British Journal of Haematology</i> , 2001, 115, 153-155.	1.2	64
134	Thromboembolism in pregnant women with mechanical prosthetic heart valves anticoagulated with low molecular weight heparin. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001, 108, 327-329.	1.1	12
135	Reversal of Metabolic Block in Glycolysis by Enzyme Replacement in Triosephosphate Isomerase-Deficient Cells. <i>Blood</i> , 1999, 94, 3193-3198.	0.6	21
136	Reversal of Metabolic Block in Glycolysis by Enzyme Replacement in Triosephosphate Isomerase-Deficient Cells. <i>Blood</i> , 1999, 94, 3193-3198.	0.6	0
137	Evidence for founder effect of the glu104asp substitution and identification of new mutations in triosephosphate isomerase deficiency. , 1997, 10, 290-294.		41
138	Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. <i>British Journal of Haematology</i> , 1996, 93, 817-821.	1.2	45
139	<i>Hepatology</i> . , 0, , 182-189.		1